Bright Minds Biosciences' BMB-101 Phase 2 trial placed on FDA partial clinical hold

Bright Minds Biosciences announced that its Phase 2 clinical trial for BMB-101, a 5-HT2C receptor agonist being investigated for developmental and epileptic encephalopathies, has been placed on a partial clinical hold by the FDA. The company provided the update on November 2, 2026.

Detected & updated continuously · Source: Nebula